Skip to main content
Erschienen in: BMC Infectious Diseases 1/2022

Open Access 01.12.2022 | COVID-19 | Research article

Epidemiological and clinical risk factors related to severe COVID-19 in Iran: a multi-center study

verfasst von: Seyed Mohammad Hashemi-Shahri, Seyed Mohammad Nasiraldin Tabatabaei, Alireza Ansari-Moghaddam, Mahdi Mohammadi, Hassan Okati-Aliabad, Seyed Mehdi Tabatabaei, Hossein Ansari, Mohammadhadi Abbasi, Khodadad Sheikhzadeh, Mehdi Zanganeh Baygi, Majid Sartipi, Sharareh Sanei-Sistani, Ali Reza Salimi Khorashad, Fatemeh Ansari-Moghadam, Neda Torab, Tahereh Khalili, Ghasem Miri-Aliabad

Erschienen in: BMC Infectious Diseases | Ausgabe 1/2022

Abstract

Background

Iran was one of the first countries to be affected by COVID-19. Identifying factors associated with the severity of COVID-19 is effective in disease management. This study investigated the epidemiological and clinical features and factors related to the severity of COVID-19 in one of the less privileged areas in Iran.

Methods

In a multi-center study, all patients admitted to Zahedan University of Medical Sciences hospitals in southeastern Iran were investigated from February 29 to April 31, 2020. Demographic, epidemiological, and clinical data of patients were extracted from medical records. Bivariate and multivariate logistic regression models were used to explore the risk factors associated with the severity of COVID-19.

Results

Among the 413 patients, 55.5% were male, and 145 (35.10%) were in a severe condition at admission time. Multivariate analysis showed that the adjusted odds of the disease severity increased in patients with older age (OR 2.27; 95% CI 1.41–3.65), substance abuse (OR 2.49; 95% CI 1.14–5.43), having one underlying disease (OR 1.52; 95% CI 0.90–2.55), having two underlying disease (OR 2.31; 95% CI 1.19–4.50), and having three or more underlying disease (OR 2.60; 95% CI 1.19–5.66).

Conclusions

COVID-19 was more severe in older patients, patients with a history of substance abuse, and patients with the underlying disease. Understanding the factors affecting the disease severity can help the clinical management of COVID-19, especially in less privileged areas where fewer resources are available.
Hinweise

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
COVID-19
Coronavirus disease
OR
Odds ratio
WHO
World Health Organization
ICU
Intensive care unit
RT-PCR
Real-time reverse-transcription-polymerase-chain-reaction
SD
Standard deviation
HFNC
High flow nasal cannula
ARDS
Acute respiratory distress syndrome
AKI
Acute kidney injury
ACE2
Angiotensin-converting enzyme 2

Background

The SARS-CoV-2 has caused a global outbreak and is a significant public health issue worldwide. This virus has spread dramatically since its emergence in China at the end of 2019 [1]. On February 11, 2020, the World Health Organization (WHO) announced a new name for the epidemic disease caused by novel coronavirus: COVID-19 [2]. COVID-19 pandemic was declared by the WHO worldwide. Until the writing of this manuscript, it was most widespread in the United States of America, Brazil, India, Russian Federation, South Africa, Peru, Mexico, Colombia, Chile, and Iran, respectively. In the meantime, 249 (5.74%) death of all 369,911 confirmed patients in Iran occurred [3]. However, there is no comprehensive report regarding risk factors related to severe COVID-19 disease in Iran.
Regarding the risk factors for the severity of COVID-19, three pooled studies in China showed that 20.1% of patients developed acute respiratory distress syndrome. Furthermore, 25.9% required ICU admission, 8.3% invasive mechanical ventilation, and 3.2% extracorporeal membrane oxygenation for refractory hypoxemia [46]. However, the ratio for severe COVID-19 patients is dissimilar in different countries [1, 7].
There is evidence that hypertension, respiratory disease, cardiovascular disease increase the risk of severe COVID-19 [810], and men are at higher risk [11]. However, it seems that health records are often incomplete or inaccurate [12], and it is expected that the severity pattern of COVID-19 and its risk factors will change soon. Morbidity to severe COVID-19 will increase the risk of death and consequently impose more expense on the health system. Therefore, it gives the impression that the estimation of risk factors for severe COVID-19 could be helpful for physicians to manage the patient treatment and effectively prioritize resources for patients with the highest risk [13], especially in deprived regions. Evidence shows that individuals with lower socioeconomic status during the COVID-19 pandemic may be more vulnerable and neglected, possibly because of disease burden, poor health literacy and access to healthcare [14]. Social factors that either lead to barriers to timely access to care or create a situation in which patients consider the delay in care the most reasonable option influence the disparities in outcomes between COVID-19 patients [15].
To our knowledge, no previous report has been published from patients with severe conditions and their characteristics in less privileged areas of Iran. Sistan and Baluchistan province is located in the southeast of Iran and has common borders with Pakistan and Afghanistan. This province has the lowest position in the development indices of the provinces of Iran. Zahedan is the capital of Sistan and Baluchestan province [16]. It is hypothesized that the characteristics and risk factors for COVID-19 are different in this area. Therefore, we aimed to determine the potential risk factors of severe COVID-19 patients and describe patients’ epidemiological and clinical characteristics during hospitalization. As the first study of this region, the results could also provide the basis for comparison in future epidemiological studies.

Methods

Study design and population

This study was carried out on 413 COVID-19 patients in all hospitals affiliated with Zahedan University of Medical Sciences, southeast of Iran. All patients diagnosed with COVID-19 according to WHO interim guidance [17] between February 29, 2020, and April 31, 2020, were included in the study. These hospitals were referral for the transfer of patients with COVID-19 from other medical centers in Zahedan. Therefore, the current study considered all adult inpatients hospitalized for COVID-19 during the mentioned time.

Evaluation of clinical results

According to the WHO clinical management of COVID-19 guideline, symptomatic patients without evidence of viral pneumonia or hypoxia were classified as a mild disease. Patients with clinical signs of pneumonia but no signs of severe pneumonia were grouped as a moderate disease. Patients with oxygen support were classified as a severe disease, and those with further complications were classified as a critically ill disease [17].

Data collection

Epidemiological and demographic characteristics and clinical data (symptoms, underlying disease, treatments, complications after admission, and outcomes) were extracted from medical records. In addition, the complementary data were collected by interviews with patients or their companions through two well-informed infectious disease residents and one anesthesia resident during hospitalization and referring to health centers during the early stage of the disease. Exposure history was defined as exposure to people with confirmed COVID-19 infection. Special and sub-special physicians approved all clinical data, symptoms, and signs based on standard definitions. Two researchers checked all data.
COVID-19 detection in respiratory specimens by RT-PCR methods was supervised by the center for disease control and prevention at the ministry of health in Iran. At the commence of the epidemic, the throat-swab specimens obtained from COVID-19 suspects were sent to the reference laboratory at Tehran University of Medical Sciences (school of public health) and Pasteur Institute of Iran. From March 11, 2020, the specimens were examined in a laboratory launching for COVID-19 detection in Zahedan city. The throat-swab samples were obtained from patients with fever, cough, and dyspnea symptoms. A confirmed case was defined as a suspected case with a positive test of RT-PCR assay on respiratory specimens.

Statistical analysis

The absolute frequency and percent were used to describe the categorical variables. The mean and standard deviation was used to summarize continuous variables. Differences between severe and non-severe patients regarding epidemiological and clinical factors and underlying diseases were compared using independent samples t-test, chi-square test, Fisher’s exact test. Bivariate and multivariate logistic regression models were used to explore the risk factors associated with disease severity. The logistic regression was chosen for multivariate analysis based on previous findings and clinical constraints considering the collinearity before fitting the model. We excluded variables from the bivariate analysis if their between-group differences were not significant, accuracy was unconfirmed, and the number of events was too small to calculate odds ratios. The data were analyzed in Stata.16, and the significance level was considered as 0.05.

Results

Of 413 patients admitted to hospitals, 55.5% were male, 38.5% had aged more than 50. The mean age of the patients was 45.05 ± 17.38, ranging from 10 to 92 years. Regarding epidemiological characteristics, 9% and 3.9% of patients reported drug use and cigarette smoking, respectively. Patients who traveled to high-risk areas within 14 days before the onset of symptoms were 13.6%. Close contact with a respiratory patient in a medical center, family, and workplace was 5.9%, 9.2%, and 2.7%, respectively. About 4% of patients reported a history of close contact with a COVID19 patient within 14 days before the onset of symptoms. Among patients, 41.4% used mask protection, and 54.7% personally went to a medical center. At admission, 145 (35.10%) patients were in severe and 268 (64.90%) non-severe conditions. There was a significant relationship between age and severity of COVID-19. The odds of severe disease were 3.38 times greater in patients aged more than 50 years, and it was 2.09 times greater in substance abuse cases. Patients referred to the hospital by ambulance (OR 3.53) were more likely to be in a severe condition of COVID-19 compared to those who went to the hospital personally. Although wearing a mask decreased the odds of severity (OR 0.38), there was no significant relationship between the mask protection and the disease severity. There were 16 (3.9%) cigarette smokers, and smoking was not the predictor of severity among COVID-19 patients (Table 1).
Table 1
Demographic and epidemiological characteristics of severe COVID-19 patients in the southeast Iran
Demographics and epidemiological characteristics
Total
Severe
OR (95% CI)
N (%)
N (%)
Age (year)
   
 Less/equal 50
254 (61.5)
62 (24.4)
1
 More than 50
159 (38.5)
83 (52.2)
3.38 (2.22,5.16)*
Sex
   
 Female
184 (44.5)
65 (35.3)
1
 Male
229 (55.5)
80 (34.9)
0.98 (0.66,1.48)NS
Cigarette smoking
   
 No
397 (96.1)
138 (34.8)
1
 Yes
16 (3.9)
7 (43.8)
1.46 (0.53,4.00) NS
Substance abuse
   
 No
376 (91)
126 (33.5)
1
 Yes
37 (9)
19 (51.4)
2.09 (1.06,4.13)*
Travel to high-risk areas
   
 No
357 (86.4)
136 (38.1)
1
 Yes
56 (13.6)
9 (16.1)
0.31 (0.14,0.65)*
Go to the medical care center within 14 days before the onset of symptoms
   
 No
362 (87.6)
122 (33.7)
1
 Yes
51 (12.4)
23 (45.1)
1.62 (0.89,2.92) NS
Close contact with a respiratory patient within 14 days before the onset of symptoms
   
 No
365 (88.3)
127 (34.8)
1
 Yes
48 (11.7)
18 (37.5)
1.12 (0.60,2.10) NS
Close contact with a respiratory patient within 14 days before the onset of symptoms in medical centers
   
 No
389 (94.1)
133 (34.2)
1
 Yes
24 (5.9)
12 (50.0)
1.93 (0.84,4.40) NS
Close contact with a respiratory patient within 14 days before the onset of symptoms in the family
   
 No
375 (90.8)
130 (34.7)
1
 Yes
38 (9.2)
15 (39.5)
1.23 (0.62,2.44) NS
Close contact with a respiratory patient within 14 days before the onset of symptoms in the workplace
   
 No
402 (97.3)
142 (35.3)
1
 Yes
11 (2.7)
3 (27.3)
0.69 (0.18,2.63) NS
History of close contact with a COVID19 patient within 14 days before the onset of symptoms
   
 No
397 (96.1)
137 (34.5)
1
 Yes
16 (3.9)
8 (50.0)
1.90 (0.70,5.17) NS
Using Mask protection
   
 No
242 (58.6)
106 (43.8)
1
 Yes
171 (41.4)
39 (22.8)
0.38 (0.25,0.59) NS
How transferred to a medical center
   
 Personally
223 (54.4)
54 (24.2)
1
 By others
104 (25.3)
44 (42.3)
2.30 (1.40,3.77)*
 By ambulance
83 (20.3)
44 (53.0)
3.53 (2.08,5.99)*
Distance protection
   
 No
404 (97.8)
142 (35.1)
1
 Yes
9 (2.2)
3 (33.3)
0.92 (0.23,3.74) NS
The duration between symptom onset and hospital admission (day)
   
 More than 1
362 (87.6)
121 (33.4)
1
 Less/equal 1
51 (12.4)
24 (47.1)
1.77 (0.98,3.20) NS
NS not significant
*Significant at the level of P < 0.05
Regarding clinical symptoms at admission, 37% of patients had a temperature of more than 37.5. The most prevalent symptoms were cough (71.2%), breath shortness (61.2%), fever (32.2%), shiver (29%), and bruising (28.4%). An abnormal computed tomography was found in 94.5%. In univariate analysis, cough, shortness of breath, abdominal pain, lack of appetite, and loss of consciousness were related to the disease severity among COVID-19 patients. Shortness of breath increased the odds of severe COVID-19 (OR 1.93). The odds of severe COVID-19 was significantly greater in patients with abdominal pain (OR 7.7), seizure (OR 27.1), and loss of consciousness (OR 12.4) (Table 2). Among all patients, 1.4% had a runny nose, and 1.7% had no sign.
Table 2
Clinical characteristics and signs of severe COVID-19 patients in the southeast of Iran
Clinical characteristics at admission*
Total
Severe
OR (95% CI)
N (%)
N (%)**
Temperature
   
 Less/equal 37.5
257 (63)
88 (34.2)
1
 37.5–38.5
107 (26.2)
38 (35.5)
1.06 (0.66,1.70)NS
 More than 38.5
44 (10.8)
17 (38.6)
1.21 (0.62,2.34) NS
Shiver
   
 No
294 (71)
106 (36.1)
1
 Yes
119 (29)
39 (32.8)
0.86 (0.55,1.36) NS
Fever
   
 No
320 (77.5)
112 (35.0)
1
 Yes
93 (22.5)
33 (35.5)
0.85 (0.35,1.73) NS
Cough
   
 No
119 (28.8)
54 (45.4)
1
 Yes
294 (71.2)
91 (31.0)
0.54 (0.35,0.84)*
Shortness of breath
   
 No
160 (38.7)
42 (26.3)
1
 Yes
253 (61.2)
103 (40.7)
1.93 (1.25,2.97)*
General weakness
   
 No
348 (84.22)
117 (33.6)
1
 Yes
65 (15.8)
28 (43.1)
1.49 (0.87,2.56) NS
Bruising
   
 No
296 (71.6)
113 (38.2)
1
 Yes
117 (28.4)
32 (27.4)
0.61 (0.38,1.08)
Sore throat
   
 No
388 (93.9)
140 (36.1)
1
 Yes
25 (6.1)
5 (20.0)
0.44 (0.16,1.21) NS
Diarrhea
   
 No
392 (95)
142 (36.2)
1
 Yes
21 (5)
3 (14.3)
0.29 (0.09,1.01) NS
Nausea
   
 No
345 (83.5)
123 (35.7)
1
 Yes
68 (16.5)
22 (32.4)
0.86 (0.50,1.50) NS
Headache
   
 No
344 (83.3)
126 (36.6)
1
 Yes
69 (16.7)
19 (27.5)
0.66 (0.37,1.16)NS
Chest pain
   
 No
401 (97)
141 (35.2)
1
 Yes
12 (3)
4 (33.3)
0.92 (0.27,3.12) NS
Abdominal pain
   
 No
403 (97.5)
137 (34.0)
1
 Yes
10 (2.5)
8 (80.0)
7.77 (1.63,37.08)*
Joint pain
   
 No
393 (95.1)
141 (35.9)
1
 Yes
20 (4.9)
4 (20.0)
0.45 (0.15,1.36) NS
Tachypnea
   
 No
408 (98.8)
141 (34.6)
1
 Yes
5 (1.2)
4 (80.0)
7.57 (0.84,68.41) NS
Abnormal lung sounds
   
 No
369 (89.3)
129 (35.0)
1
 Yes
44 (10.7)
16 (36.4)
1.06 (0.56,2.04) NS
Abnormal CT
   
 No
23 (5.5)
6 (26.1)
1
 Yes
390 (94.5)
139 (35.6)
1.57 (0.61,4.07) NS
Seizure
   
 No
410 (99.2)
143 (34.9)
1
 Yes
3 (0.8)
2 (66.7)
3.73 (0.34,41.54) NS
Lack of appetite
   
 No
361 (87.4)
120 (33.2)
1
 Yes
52 (12.6)
25 (48.1)
1.86 (1.04,3.34)*
Dizziness
   
 No
395 (95.6)
140 (35.4)
1
 Yes
18 (4.4)
5 (27.8)
0.70 (0.24,2.01) NS
Loss of consciousness
   
 No
386 (93.4)
122 (31.6)
1
 Yes
27 (6.6)
23 (85.2)
12.44 (4.21,36.76)*
Complications created during treatment*
Total
Severe
OR (95% CI)
N (%)
N (%)
Sepsis
   
 No
387 (93.6)
121 (31.3)
1
 Yes
26 (6.4)
24 (92.3)
26.38 (6.14,113.41)*
Respiratory failure
   
 No
378 (91.5)
112 (29.6)
1
 Yes
35 (8.5)
33 (94.3)
39.19 (9.24,166.10)*
Coagulopathy
   
 No
409 (99)
142 (34.7)
1
 Yes
4 (1)
3 (75.0)
5.64 (0.58,54.73)NS
Acute respiratory distress syndrome
   
 No
397 (96.1)
130 (32.7)
1
 Yes
16 (3.9)
15 (93.8)
30.81 (4.03,235.76)*
Heart failure
   
 No
403 (97.5)
136 (33.7)
1
 Yes
10 (2.5)
9 (90.0)
24.2 (3.33,249.09)*
Acute heart injury
   
 No
406 (98.3)
139 (34.2)
1
 Yes
7 (1.7)
6 (85.7)
11.52 (1.37,96.68)*
Acute kidney injury
   
 No
393 (95.1)
128 (32.6)
1
 Yes
20 (4.9)
17 (85.0)
11.73 (3.38,40.76)*
Acute liver injury
   
 No
410 (99.2)
143 (34.9)
1
 Yes
3 (0.8)
2 (66.7)
3.73 (0.34,41.54)*
Acidosis
   
 No
406 (98.3)
139 (34.2)
1
 Yes
7 (1.7)
6 (85.7)
11.52 (1.37,96.68)*
NS not significant
*Significant at the level of P < 0.05
**Percentage calculated by row
In univariate analysis, sepsis, respiratory failure, acute respiratory distress, heart failure, acute kidney and liver injury were related to the severity of disease among COVID-19 patients. The odds of severe COVID-19 was significantly greater in patients with sepsis (OR 26.3), respiratory failure (OR 39.1), acute respiratory distress syndrome (OR 30.81), heart failure (OR 24.2), acute heart injury (OR 11.5), acute kidney injury (OR 11.7), liver injury (OR 3.7) and acidosis (OR 11.5) (Table 2).
The most prevalent underlying disease among COVID-19 patients were hypertension (23.5%), diabetes (17.2%), cardiovascular disease (13.1%), chronic pulmonary disease (9.5%), and asthma (5.1%). Underlying disease, including cardiovascular disease (OR 2.43), liver disease (OR 5.74), chronic lung disease (OR 3.34), hypertension (OR 1.98), and rheumatologic disease (OR 5.8), increased the odds of severity among COVID-19 patients (Table 3). Congestive heart disease, organ transplant, and malignancy were reported in only 2 (0.5%) patients.
Table 3
Distribution of underlying disease among severe COVID-19 patients in the southeast Iran
Underlying disease
Total
Severe
OR (95% CI)
N (%)
N (%)**
Dialysis
   
 No
401 (94.8)
140 (34.9)
1
 Yes
12 (5.2)
5 (41.7)
1.33 (0.42,4.27)NS
Cardiovascular disease
   
 No
359 (86.9)
116 (32.3)
1
 Yes
54 (13.1)
29 (53.7)
2.43 (1.36,4.34)*
Diabetes
   
 No
342 (82.8)
114 (33.3)
1
 Yes
71 (17.2)
31 (43.7)
1.55 (0.92,2.61) NS
Liver disease
   
 No
405 (98)
139 (34.3)
1
 Yes
8 (2)
6 (75.0)
5.74 (1.14,28.82)*
Chronic kidney disease
   
 No
400 (96.8)
138 (34.5)
1
 Yes
13 (3.2)
7 (53.8)
2.22 (0.73,6.72) NS
Chronic neurological disease
   
 No
404 (97.8)
143 (35.4)
1
 Yes
9 (2.2)
2 (22.2)
0.52 (0.11,2.54) NS
Chronic pulmonary disease
   
 No
374 (90.5)
121 (32.4)
1
 Yes
39 (9.5)
24 (61.5)
3.34 (1.69,6.61)*
Malignant Disease
   
 No
411 (99.5)
144 (35.0)
1
 Yes
2 (0.5)
1 (50.0)
1.85 (0.12,29.86) NS
Hypertension
   
 No
316 (76.5)
99 (31.3)
1
 Yes
97 (23.5)
46 (47.4)
1.98 (1.24,3.14)*
Cerebrovascular disease
   
 No
404 (97.8)
140 (34.7)
1
 Yes
9 (2.2)
5 (55.6)
2.36 (0.62,8.92) NS
Chronic blood disease
   
 No
405 (98)
142 (35.1)
1
 Yes
8 (2)
3 (37.5)
1.11 (0.26,4.72) NS
Asthma
   
 No
392 (94.9)
136 (34.7)
1
 Yes
21 (5.1)
9 (42.9)
1.41 (0.58,3.43) NS
Congestive heart disease
   
 No
411 (99.5)
143 (34.8)
 
 Yes
2 (0.5)
2 (100.0)
 
Rheumatologic disease
   
 No
401 (97.1)
136 (33.9)
1
 Yes
12 (2.9)
9 (75.0)
5.85 (1.56,21.95)*
Organ transplant
   
 No
411 (99.5)
143 (34.8)
 
 Yes
2 (0.5)
2 (100.0)
 
Defect immune system
   
 No
400 (96.8)
140 (35.0)
1
 Yes
13 (3.2)
5 (38.5)
1.16 (0.37,3.62) NS
NS no significant
*Significant at the level of P < 0.05
**Percentage calculated by row
Among all patients, 37% had an oxygen saturation of more than 0.93, 11.4% were eventually admitted to the ICU, and 8.7% received mechanical ventilation. According to oxygen therapy, 90.6% received high flow nasal cannula (HFNC) and 8.2% invasive mechanical ventilation. The odds of severe disease increased significantly in patients admitted to ICU (OR 27.8) and mechanically ventilated patients (OR 84.9). Oxygen saturation of more than 0.93 could prevent the disease severity by 70%. The mean heart rate and respiratory rate were significantly different between the severe and non-severe patients (P < 0.001) (Table 4). About 36 (94.7%) of the severe patients were intubated. Most patients took antibiotics (91.5%) and antiviral drugs (97.3%) but were not related to severity among COVID-19 patients (P > 0.05).
Table 4
Distribution of oxygen therapy and vital sign among severe COVID-19 patients in the southeast Iran
 
Total
Severe
OR (95% CI)
N (%)
N (%)**
High flow nasal cannula
   
 No
39 (90.5)
37 (94.9)
1
 Yes
374 (9.5)
108 (28.9)
0.02 (0.005,0.093)*
Non-Invasive mechanical ventilation
   
 No
405 (98)
137 (33.8)
 
 Yes
8 (2)
8 (100.0)
 
Invasive mechanical ventilation
   
 No
379 (91.7)
112 (29.6)
1
 Yes
34 (8.3)
33 (97.1)
78.67 (10.63,582.25)*
ICU admission
   
 No
366 (88.6)
102 (27.9)
1
 Yes
47 (11.4)
43 (91.5)
27.82 (9.74,79.49)*
Intubation
   
 No
375 (90.8)
109 (29.1)
1
 Yes
38 (9.2)
36 (94.7)
43.93 (10.40,185.63)*
Mechanical ventilation
   
 No
377 (91.3)
110 (29.2)
1
 Yes
36 (8.7)
35 (97.2)
84.96 (11.50,627.82)*
Oxygen saturation
   
 More than 0.93
153 (37)
30 (19.6)
1
 Less/equal 0.93
258 (63)
114 (44.2)
3.25 (2.03,5.18)*
Mean ± SD
Low/Moderate
Sever/Critically sever
P
Heart rate
92.33 ± 12.94
97.75 ± 18.57
0.002
Respiratory rate
18.92 ± 4.37
22.19 ± 6.53
 < 0.001
Systolic blood pressure
115.95 ± 16.35
118.36 ± 19.21
0.182NS
Diastolic blood pressure
73.18 ± 11.14
74.57 ± 11.46
0.234NS
NS no significant
*Significant at the level of P < 0.05
**Percentage calculated by row
Multivariate analysis was performed on all variables found significant by univariate analysis in Tables 1, 2 and 3. Multivariate regression showed increased odds of the severity for COVID-19 was associated with older age (OR 2.27), substance abuse (OR 2.49), having one underlying disease (OR 1.52), having two underlying diseases (OR 2.31), having three or more underlying diseases (OR 2.60) (Table 5).
Table 5
Multivariate logistic regression for predictors of severity among COVID-19 patients in the southeast of Iran
Independent variables
B
S.E of Beta
P
OR
OR (95% CI)
 
Having underlying disease***
    
Lower
Upper
 No**
   
1
  
 One
0.841
0.265
0.114
1.521
0.904
2.558
 Two
0.957
0.339
0.013
2.319
1.193
4.504
 Three or more
0.913
0.397
0.016
2.604
1.197
5.665
Substance abuse
      
 No**
   
1
  
 Yes
0.913
0.397
0.022
2.493
1.144
5.432
Age
      
 > 50
   
1
  
 ≤ 50**
0.823
0.241
0.001
2.277
1.419
3.655
*Variables for Table 4 not included in the model
**Reference group
***Having underlying disease according to Table 3

Discussion

The current study investigated the clinical characteristics of patients with COVID-19 and potential risk factors for severity. Univariate analysis revealed that age, substance abuse, traveling to high-risk areas, means of transportation to a medical center, cough, shortness of breath, abdominal pain, lack of appetite, loss of consciousness, sepsis, respiratory failure, acute respiratory distress syndrome were associated with severity in COVID-19 patients. Also, heart failure, acute heart injury, acute kidney injury, acute liver injury, acidosis, cardiovascular disease, liver disease, chronic pulmonary disease, hypertension, rheumatologic disease, high flow nasal cannula oxygen therapy, invasive mechanical ventilation, ICU admission, intubation, mechanical ventilation, oxygen saturation, heart rate, and respiratory rate were associated with severity in COVID-19 patients. Multivariate analysis revealed that age, substance abuse, and underlying disease were predictors of severity in COVID-19 patients.
Among the 413 patients in this study, 145 (35.10%) were in severe condition, and older patients were at higher risk of severe disease. Inadequate immune response in older patients leads to more complicated and critical conditions such as ARDS, severe clinical manifestations, and longer disease duration [18, 19]. Other studies have reported a lower prevalence of disease severity, including 17.6% and 25.6% [20, 21], which is expected based on various definitions.
In the current study, substance abuse was a risk factor for COVID-19 severity, resulting from direct damage to the respiratory system, modulating brain and immune functions [22]. Severe disease was also associated with travel to high-risk areas. This finding highlights the importance of social distancing on viral inocula reduction [23], leading to less severe disease [24]. Exposure to confirmed cases and recent travel to the epidemic area are the host risk factors for severe COVID-19 [25].
In terms of signs, this study showed that cough, shortness of breath, abdominal pain, losing appetite, heart rate, and the number of breathing were associated with severity in COVID-19 patients. Gastrointestinal symptoms are more prevalent in severe COVID-19 patients, so 100% of these patients experience a lack of appetite. The increased viral load and the spread of the virus in the gastrointestinal tract of COVID-19 patients can lead to the severity of the disease [26]. Other studies have shown that cough, shortness of breath, and abdominal pain are common in patients with severe COVID-19 [2729]. Furthermore, high respiratory and heart rates were the risk factors for the severity in COVID-19 patients [30].
The present study showed a decreased level of consciousness, oxygen requirement at hospitalization, ICU admission, invasive mechanical ventilation, intubation, and oxygen saturation were risk factors for severity in COVID-19 patients. Previous studies have shown that only severe patients need to be admitted to the ICU, and oxygen saturation is lower in severe patients. In addition, unconsciousness, shortness of breath, oxygen therapy, invasive and non-invasive mechanical ventilation were also more common in severe patients [3134].
In the current study, complications during treatment, sepsis, respiratory failure, acute respiratory distress syndrome, heart failure, acute heart injury, acute kidney injury, and acidosis were risk factors for severity in COVID-19 patients. The cause of respiratory failure in patients with COVID-19 was impaired immune function [35]. Uncontrolled viral infection causes macrophage penetration and further damage to the lungs [36]. Serious complications such as acute respiratory distress syndrome, acute cardiac injury, acute kidney injury, and shock can occur in patients with severe COVID-19. Acute respiratory distress syndrome and acute cardiac injury are the most important barriers to treating COVID-19 patients [37]. Cardiac injury is associated with the severity of disease in patients with COVID-19 [38]. The SARS-CoV-2 affects the cardiovascular system through angiotensin-converting enzyme 2 (ACE2) and causes myocardial injury and heart failure [39, 40]. Acute kidney injury (AKI) is an indicator of disease severity. Volume depletion may be the cause of acute kidney injury [41]. The prevalence of liver dysfunction and liver injury is higher in patients with severe COVID-19. Liver impairment may be caused directly by a viral infection of the liver cells or by hepatotoxicity caused by drugs and immune-mediated inflammation [42].
In terms of underlying health conditions, cardiovascular disease, liver disease, chronic pulmonary disease, hypertension, and rheumatologic disease were risk factors for severe COVID-19 in this study. Underlying health conditions are responsible for 20% of severe COVID-19 worldwide [43]. Severe COVID-19 patients experience a higher incidence of comorbidity, a risk factor for the severity of COVID-19 pneumonia [44, 45]. Patients with established cardiovascular disease exhibited a greater angiotensin-converting enzyme 2 (ACE2) expression and probably experienced a worse condition following SARS-CoV-2 infection [46, 47]. Patients with a history of hypertension are more likely to develop severe COVID-19 as hypertension is a predictor of severe pneumonia [48, 49]. There is evidence that antihypertensive drugs prevent patients with comorbid hypertension from severe pneumonia. Chronic respiratory conditions are also associated with the severity of COVID-19 [50]. Elevated liver biochemical indicators are common in COVID‐19, resulting in severe COVID‐19 [51, 52]. Patients with rheumatic diseases are at high risk for COVID-19 infection due to their immune conditions [53]. In addition, chronic inflammatory rheumatic patients with autoimmune or immune-mediated diseases are at risk of severe COVID-19 [54].

Conclusions

COVID-19 was more severe in older patients, patients with a history of substance abuse, and patients with underlying disease. Understanding the factors affecting the disease severity can help the clinical management of COVID-19, especially in less privileged areas where fewer resources are available.
One of the strengths of the present study is that the patients were selected from a less privileged area which can draw the attention of health policymakers to this area. Another strength of the study is the multi-center nature of the survey, representing the population. This study had some limitations: First, the small sample size, leading to insignificant statistical results. Therefore, the results of this study should be interpreted with caution. Further studies are needed to investigate potential risk factors of severity in patients with COVID-19 with large sample size. Second, the information was collected as a self-report in some cases, leading to recall bias.

Acknowledgements

The authors would like to thank all the health care workers in Zahedan University of Medical Sciences hospitals who participated in treating patients with COVID-19.

Declarations

The ethics committee of Zahedan University of Medical Sciences approved this study protocol (IR.ZAUMS.REC.1399.009). Permits for access to clinical/personal data of patients used in the study were issued by the Vice-Chancellor for Research of Zahedan University of Medical Sciences. Written informed consent was obtained from all patients. If it was impossible to obtain informed consent from the patient due to a critical illness, their relatives to be asked to give written informed consent.
Not applicable.

Competing interests

The authors declare that they have no conflict of interest.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Literatur
1.
Zurück zum Zitat Lai C-C, Shih T-P, Ko W-C, Tang H-J, Hsueh P-R. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and corona virus disease-2019 (COVID-19): the epidemic and the challenges. Int J Antimicrob Agents. 2020;55:105924.PubMedPubMedCentral Lai C-C, Shih T-P, Ko W-C, Tang H-J, Hsueh P-R. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and corona virus disease-2019 (COVID-19): the epidemic and the challenges. Int J Antimicrob Agents. 2020;55:105924.PubMedPubMedCentral
4.
Zurück zum Zitat Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–13.PubMedPubMedCentral Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–13.PubMedPubMedCentral
5.
Zurück zum Zitat Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.PubMedPubMedCentral Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.PubMedPubMedCentral
6.
Zurück zum Zitat Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. Lancet. 2020;395(10223):470–3.PubMedPubMedCentral Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. Lancet. 2020;395(10223):470–3.PubMedPubMedCentral
7.
Zurück zum Zitat Shim E, Tariq A, Choi W, Lee Y, Chowell G. Transmission potential and severity of COVID-19 in South Korea. Int J Infect Dis. 2020;93:339–44.PubMedPubMedCentral Shim E, Tariq A, Choi W, Lee Y, Chowell G. Transmission potential and severity of COVID-19 in South Korea. Int J Infect Dis. 2020;93:339–44.PubMedPubMedCentral
8.
Zurück zum Zitat Huang R, Zhu L, Xue L, Liu L, Yan X, Wang J, et al. Clinical findings of patients with coronavirus disease 2019 in Jiangsu province, China: a retrospective, multi-center study. PLoS Neglect Trop Dis. 2020;14(5):e0008280. Huang R, Zhu L, Xue L, Liu L, Yan X, Wang J, et al. Clinical findings of patients with coronavirus disease 2019 in Jiangsu province, China: a retrospective, multi-center study. PLoS Neglect Trop Dis. 2020;14(5):e0008280.
9.
Zurück zum Zitat Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061–9.PubMedPubMedCentral Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061–9.PubMedPubMedCentral
10.
Zurück zum Zitat Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis. Int J Infect Dis. 2020;10:1016. Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis. Int J Infect Dis. 2020;10:1016.
11.
Zurück zum Zitat Livingston E, Bucher K. Coronavirus disease 2019 (COVID-19) in Italy. JAMA. 2020;323(14):1335.PubMed Livingston E, Bucher K. Coronavirus disease 2019 (COVID-19) in Italy. JAMA. 2020;323(14):1335.PubMed
12.
Zurück zum Zitat Fang L, Gao P, Bao H, Tang X, Wang B, Feng Y, et al. Chronic obstructive pulmonary disease in China: a nationwide prevalence study. Lancet Respir Med. 2018;6(6):421–30.PubMedPubMedCentral Fang L, Gao P, Bao H, Tang X, Wang B, Feng Y, et al. Chronic obstructive pulmonary disease in China: a nationwide prevalence study. Lancet Respir Med. 2018;6(6):421–30.PubMedPubMedCentral
13.
Zurück zum Zitat Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020;46(5):846–8.PubMed Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020;46(5):846–8.PubMed
14.
Zurück zum Zitat Zhu Y, Duan M-J, Dijk HH, Freriks RD, Dekker LH, Mierau JO. Association between socioeconomic status and self-reported, tested and diagnosed COVID-19 status during the first wave in the Northern Netherlands: a general population-based cohort from 49 474 adults. BMJ Open. 2021;11(3):e048020.PubMed Zhu Y, Duan M-J, Dijk HH, Freriks RD, Dekker LH, Mierau JO. Association between socioeconomic status and self-reported, tested and diagnosed COVID-19 status during the first wave in the Northern Netherlands: a general population-based cohort from 49 474 adults. BMJ Open. 2021;11(3):e048020.PubMed
15.
Zurück zum Zitat Azar KM, Shen Z, Romanelli RJ, Lockhart SH, Smits K, Robinson S, et al. Disparities in outcomes among COVID-19 patients in a large health care system in California: study estimates the COVID-19 infection fatality rate at the US county level. Health Aff. 2020;39(7):1253–62. Azar KM, Shen Z, Romanelli RJ, Lockhart SH, Smits K, Robinson S, et al. Disparities in outcomes among COVID-19 patients in a large health care system in California: study estimates the COVID-19 infection fatality rate at the US county level. Health Aff. 2020;39(7):1253–62.
16.
Zurück zum Zitat Afrakhteh H. The problems of regional development and border cities: A case study of Zahedan. Iran Cities. 2006;23(6):423–32. Afrakhteh H. The problems of regional development and border cities: A case study of Zahedan. Iran Cities. 2006;23(6):423–32.
17.
Zurück zum Zitat World Health Organization. Clinical management of COVID-19: interim guidance, 27 May 2020. Geneva: World Health Organization; 2020. World Health Organization. Clinical management of COVID-19: interim guidance, 27 May 2020. Geneva: World Health Organization; 2020.
18.
Zurück zum Zitat Wu C, Chen X, Cai Y, Zhou X, Xu S, Huang H, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Internal Med. 2020;180:934–43. Wu C, Chen X, Cai Y, Zhou X, Xu S, Huang H, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Internal Med. 2020;180:934–43.
19.
Zurück zum Zitat Liu Y, Mao B, Liang S, Yang J-W, Lu H-W, Chai Y-H, et al. Association between ages and clinical characteristics and outcomes of coronavirus disease 2019. Eur Respir J. 2020;55:5. Liu Y, Mao B, Liang S, Yang J-W, Lu H-W, Chai Y-H, et al. Association between ages and clinical characteristics and outcomes of coronavirus disease 2019. Eur Respir J. 2020;55:5.
20.
Zurück zum Zitat Tian S, Hu N, Lou J, Chen K, Kang X, Xiang Z, et al. Characteristics of COVID-19 infection in Beijing. J Infect. 2020;80:401–6.PubMedPubMedCentral Tian S, Hu N, Lou J, Chen K, Kang X, Xiang Z, et al. Characteristics of COVID-19 infection in Beijing. J Infect. 2020;80:401–6.PubMedPubMedCentral
21.
Zurück zum Zitat Fu L, Wang B, Yuan T, Chen X, Ao Y, Fitzpatrick T, et al. Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: a systematic review and meta-analysis. J Infect. 2019;202080:656–65. Fu L, Wang B, Yuan T, Chen X, Ao Y, Fitzpatrick T, et al. Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: a systematic review and meta-analysis. J Infect. 2019;202080:656–65.
22.
Zurück zum Zitat Wei Y, Shah R. Substance use disorder in the COVID-19 pandemic: a systematic review of vulnerabilities and complications. Pharmaceuticals. 2020;13(7):155.PubMedCentral Wei Y, Shah R. Substance use disorder in the COVID-19 pandemic: a systematic review of vulnerabilities and complications. Pharmaceuticals. 2020;13(7):155.PubMedCentral
23.
Zurück zum Zitat Dalton CB, Corbett SJ, Katelaris AL. Pre-emptive low cost social distancing and enhanced hygiene implemented before local COVID-19 transmission could decrease the number and severity of cases. Med J Aust. 2020;212(10):1. Dalton CB, Corbett SJ, Katelaris AL. Pre-emptive low cost social distancing and enhanced hygiene implemented before local COVID-19 transmission could decrease the number and severity of cases. Med J Aust. 2020;212(10):1.
24.
Zurück zum Zitat Yu X, Sun S, Shi Y, Wang H, Zhao R, Sheng J. SARS-CoV-2 viral load in sputum correlates with risk of COVID-19 progression. Crit Care. 2020;24:1–4. Yu X, Sun S, Shi Y, Wang H, Zhao R, Sheng J. SARS-CoV-2 viral load in sputum correlates with risk of COVID-19 progression. Crit Care. 2020;24:1–4.
25.
Zurück zum Zitat Shi Y, Yu X, Zhao H, Wang H, Zhao R, Sheng J. Host susceptibility to severe COVID-19 and establishment of a host risk score: findings of 487 cases outside Wuhan. Crit Care. 2020;24(1):1–4. Shi Y, Yu X, Zhao H, Wang H, Zhao R, Sheng J. Host susceptibility to severe COVID-19 and establishment of a host risk score: findings of 487 cases outside Wuhan. Crit Care. 2020;24(1):1–4.
26.
Zurück zum Zitat Pan L, Mu M, Yang P, Sun Y, Wang R, Yan J, et al. Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study. Am J Gastroenterol. 2020;115:766–73.PubMed Pan L, Mu M, Yang P, Sun Y, Wang R, Yan J, et al. Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study. Am J Gastroenterol. 2020;115:766–73.PubMed
27.
Zurück zum Zitat Zheng Z, Peng F, Xu B, Zhao J, Liu H, Peng J, et al. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. J Infect. 2020;81(2):e16–25.PubMedPubMedCentral Zheng Z, Peng F, Xu B, Zhao J, Liu H, Peng J, et al. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. J Infect. 2020;81(2):e16–25.PubMedPubMedCentral
28.
Zurück zum Zitat Mo P, Xing Y, Xiao Y, Deng L, Zhao Q, Wang H, et al. Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China. Clin Infect Dis. 2020;73(11):e4208–13. Mo P, Xing Y, Xiao Y, Deng L, Zhao Q, Wang H, et al. Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China. Clin Infect Dis. 2020;73(11):e4208–13.
29.
Zurück zum Zitat Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol. 2020;146(1):110–8.PubMedPubMedCentral Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol. 2020;146(1):110–8.PubMedPubMedCentral
30.
Zurück zum Zitat Zhang J, Yu M, Tong S, Liu L-Y, Tang L-V. Predictive factors for disease progression in hospitalized patients with coronavirus disease 2019 in Wuhan, China. J Clin Virol. 2020;127:104392.PubMedPubMedCentral Zhang J, Yu M, Tong S, Liu L-Y, Tang L-V. Predictive factors for disease progression in hospitalized patients with coronavirus disease 2019 in Wuhan, China. J Clin Virol. 2020;127:104392.PubMedPubMedCentral
31.
Zurück zum Zitat Liu Y, Yan L-M, Wan L, Xiang T-X, Le A, Liu J-M, et al. Viral dynamics in mild and severe cases of COVID-19. Lancet Infect Dis. 2020;20(6):656–7.PubMedPubMedCentral Liu Y, Yan L-M, Wan L, Xiang T-X, Le A, Liu J-M, et al. Viral dynamics in mild and severe cases of COVID-19. Lancet Infect Dis. 2020;20(6):656–7.PubMedPubMedCentral
32.
Zurück zum Zitat Wei Y-Y, Wang R-R, Zhang D-W, Tu Y-H, Chen C-S, Ji S, et al. Risk factors for severe COVID-19: Evidence from 167 hospitalized patients in Anhui, China. J Infect. 2020;81(1):e89–92.PubMedPubMedCentral Wei Y-Y, Wang R-R, Zhang D-W, Tu Y-H, Chen C-S, Ji S, et al. Risk factors for severe COVID-19: Evidence from 167 hospitalized patients in Anhui, China. J Infect. 2020;81(1):e89–92.PubMedPubMedCentral
33.
Zurück zum Zitat Bhargava A, Fukushima EA, Levine M, Zhao W, Tanveer F, Szpunar SM, et al. Predictors for severe COVID-19 infection. Clin Infect Dis. 2020;71(8):1962–8.PubMed Bhargava A, Fukushima EA, Levine M, Zhao W, Tanveer F, Szpunar SM, et al. Predictors for severe COVID-19 infection. Clin Infect Dis. 2020;71(8):1962–8.PubMed
34.
Zurück zum Zitat Zhang J, Wang X, Jia X, Li J, Hu K, Chen G, et al. Risk factors for disease severity, unimprovement, and mortality of COVID-19 patients in Wuhan, China. Clin Microbiol Infect. 2020;26(6):767–72.PubMedPubMedCentral Zhang J, Wang X, Jia X, Li J, Hu K, Chen G, et al. Risk factors for disease severity, unimprovement, and mortality of COVID-19 patients in Wuhan, China. Clin Microbiol Infect. 2020;26(6):767–72.PubMedPubMedCentral
35.
Zurück zum Zitat Giamarellos-Bourboulis EJ, Netea MG, Rovina N, Akinosoglou K, Antoniadou A, Antonakos N, et al. Complex immune dysregulation in COVID-19 patients with severe respiratory failure. Cell Host Microbe. 2020;27(6):992-1000.e3.PubMedPubMedCentral Giamarellos-Bourboulis EJ, Netea MG, Rovina N, Akinosoglou K, Antoniadou A, Antonakos N, et al. Complex immune dysregulation in COVID-19 patients with severe respiratory failure. Cell Host Microbe. 2020;27(6):992-1000.e3.PubMedPubMedCentral
36.
Zurück zum Zitat Li H, Liu L, Zhang D, Xu J, Dai H, Tang N, et al. SARS-CoV-2 and viral sepsis: observations and hypotheses. Lancet. 2020;395(10235):1517–20.PubMedPubMedCentral Li H, Liu L, Zhang D, Xu J, Dai H, Tang N, et al. SARS-CoV-2 and viral sepsis: observations and hypotheses. Lancet. 2020;395(10235):1517–20.PubMedPubMedCentral
38.
Zurück zum Zitat Santoso A, Pranata R, Wibowo A, Al-Farabi MJ, Huang I, Antariksa B. Cardiac injury is associated with mortality and critically ill pneumonia in COVID-19: a meta-analysis. Am J Emerg Med. 2020;44:352–7.PubMedPubMedCentral Santoso A, Pranata R, Wibowo A, Al-Farabi MJ, Huang I, Antariksa B. Cardiac injury is associated with mortality and critically ill pneumonia in COVID-19: a meta-analysis. Am J Emerg Med. 2020;44:352–7.PubMedPubMedCentral
39.
Zurück zum Zitat Long B, Brady WJ, Koyfman A, Gottlieb M. Cardiovascular complications in COVID-19. Am J Emerg Med. 2020;38(7):1504–7.PubMedPubMedCentral Long B, Brady WJ, Koyfman A, Gottlieb M. Cardiovascular complications in COVID-19. Am J Emerg Med. 2020;38(7):1504–7.PubMedPubMedCentral
40.
Zurück zum Zitat Clerkin KJ, Fried JA, Raikhelkar J, Sayer G, Griffin JM, Masoumi A, et al. COVID-19 and cardiovascular disease. Circulation. 2020;141(20):1648–55.PubMed Clerkin KJ, Fried JA, Raikhelkar J, Sayer G, Griffin JM, Masoumi A, et al. COVID-19 and cardiovascular disease. Circulation. 2020;141(20):1648–55.PubMed
41.
Zurück zum Zitat Ronco C, Reis T, Husain-Syed F. Management of acute kidney injury in patients with COVID-19. Lancet Respir Med. 2020;8(7):738–42.PubMedPubMedCentral Ronco C, Reis T, Husain-Syed F. Management of acute kidney injury in patients with COVID-19. Lancet Respir Med. 2020;8(7):738–42.PubMedPubMedCentral
42.
Zurück zum Zitat Zhang C, Shi L, Wang F-S. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol. 2020;5(5):428–30.PubMedPubMedCentral Zhang C, Shi L, Wang F-S. Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol. 2020;5(5):428–30.PubMedPubMedCentral
43.
Zurück zum Zitat Clark A, Jit M, Warren-Gash C, Guthrie B, Wang HH, Mercer SW, et al. Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study. Lancet Glob Health. 2020;8(8):e1003–17.PubMedPubMedCentral Clark A, Jit M, Warren-Gash C, Guthrie B, Wang HH, Mercer SW, et al. Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study. Lancet Glob Health. 2020;8(8):e1003–17.PubMedPubMedCentral
44.
Zurück zum Zitat Li K, Wu J, Wu F, Guo D, Chen L, Fang Z, et al. The clinical and chest CT features associated with severe and critical COVID-19 pneumonia. Investig Radiol. 2020;55(6):327–31. Li K, Wu J, Wu F, Guo D, Chen L, Fang Z, et al. The clinical and chest CT features associated with severe and critical COVID-19 pneumonia. Investig Radiol. 2020;55(6):327–31.
45.
Zurück zum Zitat Yin Q, Fu Z, Xie J, Yang J, Li F, Zhu W, et al. Analysis of Risk Factors of Severe COVID-19 Patients. 2020. Yin Q, Fu Z, Xie J, Yang J, Li F, Zhu W, et al. Analysis of Risk Factors of Severe COVID-19 Patients. 2020.
46.
Zurück zum Zitat Chen L, Li X, Chen M, Feng Y, Xiong C. The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2. Cardiovasc Res. 2020;116(6):1097–100.PubMed Chen L, Li X, Chen M, Feng Y, Xiong C. The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2. Cardiovasc Res. 2020;116(6):1097–100.PubMed
47.
Zurück zum Zitat Li B, Yang J, Zhao F, Zhi L, Wang X, Liu L, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol. 2020;109(5):531–8.PubMed Li B, Yang J, Zhao F, Zhi L, Wang X, Liu L, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol. 2020;109(5):531–8.PubMed
48.
Zurück zum Zitat Liu S, Luo H, Wang Y, Cuevas LE, Wang D, Ju S, et al. Clinical characteristics and risk factors of patients with severe COVID-19 in Jiangsu province, China: a retrospective multicentre cohort study. BMC Infect Dis. 2020;20(1):1–9. Liu S, Luo H, Wang Y, Cuevas LE, Wang D, Ju S, et al. Clinical characteristics and risk factors of patients with severe COVID-19 in Jiangsu province, China: a retrospective multicentre cohort study. BMC Infect Dis. 2020;20(1):1–9.
49.
Zurück zum Zitat Liu X, Zhou H, Zhou Y, Wu X, Zhao Y, Lu Y, et al. Risk factors associated with disease severity and length of hospital stay in COVID-19 patients. J Infect. 2020;81(1):e95–7.PubMedPubMedCentral Liu X, Zhou H, Zhou Y, Wu X, Zhao Y, Lu Y, et al. Risk factors associated with disease severity and length of hospital stay in COVID-19 patients. J Infect. 2020;81(1):e95–7.PubMedPubMedCentral
50.
Zurück zum Zitat Izcovich A, Ragusa M, Tortosa F, Lavena Marzio MA, Agnoletti C, Bengolea A, et al. Prognostic factors for severity and mortality in patients infected with COVID-19: a systematic review. PLoS ONE. 2020;15(11):e0241955.PubMedPubMedCentral Izcovich A, Ragusa M, Tortosa F, Lavena Marzio MA, Agnoletti C, Bengolea A, et al. Prognostic factors for severity and mortality in patients infected with COVID-19: a systematic review. PLoS ONE. 2020;15(11):e0241955.PubMedPubMedCentral
51.
Zurück zum Zitat Wu Y, Li H, Guo X, Yoshida EM, Mendez-Sanchez N, Sandri GBL, et al. Incidence, risk factors, and prognosis of abnormal liver biochemical tests in COVID-19 patients: a systematic review and meta-analysis. Hepatol Int. 2020;14:1–17. Wu Y, Li H, Guo X, Yoshida EM, Mendez-Sanchez N, Sandri GBL, et al. Incidence, risk factors, and prognosis of abnormal liver biochemical tests in COVID-19 patients: a systematic review and meta-analysis. Hepatol Int. 2020;14:1–17.
52.
Zurück zum Zitat Kulkarni AV, Kumar P, Tevethia HV, Premkumar M, Arab JP, Candia R, et al. Systematic review with meta-analysis: liver manifestations and outcomes in COVID-19. Alimentary Pharmacol Therap. 2020;52(4):584–99. Kulkarni AV, Kumar P, Tevethia HV, Premkumar M, Arab JP, Candia R, et al. Systematic review with meta-analysis: liver manifestations and outcomes in COVID-19. Alimentary Pharmacol Therap. 2020;52(4):584–99.
53.
Zurück zum Zitat Gianfrancesco MA, Hyrich KL, Gossec L, Strangfeld A, Carmona L, Mateus EF, et al. Rheumatic disease and COVID-19: initial data from the COVID-19 global rheumatology alliance provider registries. Lancet Rheumatol. 2020;2(5):e250–3.PubMedPubMedCentral Gianfrancesco MA, Hyrich KL, Gossec L, Strangfeld A, Carmona L, Mateus EF, et al. Rheumatic disease and COVID-19: initial data from the COVID-19 global rheumatology alliance provider registries. Lancet Rheumatol. 2020;2(5):e250–3.PubMedPubMedCentral
54.
Zurück zum Zitat Pablos J, Galindo M, Carmona L, Retuerto M, Lledó A, Blanco R, et al. Clinical outcomes of patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched-cohort study. Ann Rheum Dis. 2020;79(12):1544–9.PubMed Pablos J, Galindo M, Carmona L, Retuerto M, Lledó A, Blanco R, et al. Clinical outcomes of patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched-cohort study. Ann Rheum Dis. 2020;79(12):1544–9.PubMed
Metadaten
Titel
Epidemiological and clinical risk factors related to severe COVID-19 in Iran: a multi-center study
verfasst von
Seyed Mohammad Hashemi-Shahri
Seyed Mohammad Nasiraldin Tabatabaei
Alireza Ansari-Moghaddam
Mahdi Mohammadi
Hassan Okati-Aliabad
Seyed Mehdi Tabatabaei
Hossein Ansari
Mohammadhadi Abbasi
Khodadad Sheikhzadeh
Mehdi Zanganeh Baygi
Majid Sartipi
Sharareh Sanei-Sistani
Ali Reza Salimi Khorashad
Fatemeh Ansari-Moghadam
Neda Torab
Tahereh Khalili
Ghasem Miri-Aliabad
Publikationsdatum
01.12.2022
Verlag
BioMed Central
Schlagwort
COVID-19
Erschienen in
BMC Infectious Diseases / Ausgabe 1/2022
Elektronische ISSN: 1471-2334
DOI
https://doi.org/10.1186/s12879-022-07165-0

Weitere Artikel der Ausgabe 1/2022

BMC Infectious Diseases 1/2022 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.